

PRESS RELEASE
19 June 2013



Resolutions at BioInvent's Extraordinary General Meeting

Lund, Sweden – 19 June 2013 – BioInvent International AB (OMXS: BINV)

In accordance with the proposal previously communicated, the Extraordinary General Meeting of BioInvent today 19 June resolved on an amendment of the articles of association and on a reduction of the Company's share capital for the purpose of covering part of the Company's loss while at the same time better adapt the size of the share capital to the Company's business.

In accordance with the Board's proposal, the EGM resolved on a reduction of the Company's share capital and to amend the limits for the share capital in the articles of association for the purpose of enabling the reduction. The reduction shall be made without retirement of shares and without repayment to the shareholders, and means that the quotient value of the shares is reduced by SEK 0.19 from SEK 0.27 to SEK 0.08. The purpose is to cover part of the Company's reported loss for the first quarter 2013, while at the same time better adapt the size of the share capital to the Company's business. The reduction does not affect the parent company's total equity.

To the editors:

About BioInvent

BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer. The Company's pipeline currently includes three product candidates for the treatment of cancer.

The Company's competitive position is underpinned by n-CoDeR[®], a proprietary antibody development platform. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of the new drug, and provide BioInvent the right to milestone payments and royalties on sales. These partners include Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. More information is available at www.bioinvent.com.

For further information, please contact:

Cristina Glad
President and CEO
+46 (0)46 286 85 51
+46 (0)708 16 85 70
cristina.glad@bioinvent.com

BioInvent International AB (publ)

Co. reg. No. 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50

info@bioinvent.com
www.bioinvent.com

Legal disclaimer

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 11:30 a.m. CET, on 19 June, 2013.